National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 11/06/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Localized Non-Hodgkin Lymphoma in Children and Adolescents






Disseminated Childhood B-cell Non-Hodgkin Lymphoma






Disseminated Childhood Lymphoblastic Lymphoma






Disseminated Childhood Anaplastic Large Cell Lymphoma






Recurrent Childhood Non-Hodgkin Lymphoma






Lymphoproliferative Disease Associated With Immunodeficiency in Children






Get More Information From NCI







Changes to This Summary (11/06/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
You CAN Quit Smoking Now!
Changes to This Summary (11/06/2008)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added text to state that NHL in infants is rare and retrospective review demonstrated an inferior outcome for infants when compared to older patients with NHL (cited Mann et al. as reference 4). [Level of evidence: 3iiA].

Cellular Classification

Added text about a case report of a 14 year old boy with refractory primary central nervous system lymphoma, with an excellent result of repeated intravenous and intraventricular doses of rituxumab (cited Akyuz et al. as reference 41).

Disseminated Childhood B-cell Non-Hodgkin Lymphoma

Added text about data that suggests that secondary cytogenetic abnormalities, other than c-myc rearrangement, are associated with an inferior outcome. The prognostic role of minimal residual disease in the treatment of Burkitt leukemia remains unclear with results from a single study suggest inferior outcome for patients with detectable MRD. Testicular disease at diagnosis does not seem to confer poor prognosis (cited Onciu et al., Mussolin et al., and Dalle et al. as references 7, 8 and 9, respectively).

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov